Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device Clinical Trials

St. Jude Plans Trial To Study Renal Denervation Outcomes

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Landmark trial will evaluate whether reductions in blood pressure caused by renal denervation translate to clinical improvements in patients with hard-to-treat hypertension.

You may also be interested in...



Research In Brief

St Jude launches post-market study of its renal denervation system. More research news

Boston Scientific Enters Renal Denervation Market Via Vessix Acquisition

Deal gives Boston Scientific access to the V2 radiofrequency energy-based renal denervation catheter system for drug-resistant hypertension.

New Products In Brief

Recent approvals and launches include St. Jude Medical’s EnligHTN renal denervation system for hypertension and Zeltiq Aesthetics’ expanded CoolSculpting clearance for fat reduction.

Table

View full table

Related Content

Medtech Insight

Topics

Related Companies

Tags:
Medical Device Clinical Trials
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS075318

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By